Blog Archive
-
▼
2007
(17)
-
▼
October
(8)
- INNATE PHARMA, NEW PHASE IIa TRIAL WITH IPH 1101 I...
- BioAlliance Pharma, promising in vivo results for ...
- Flamel Technologies, Positive Results of a Phase I...
- bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First...
- VIVALIS , FIRST RESEARCH LICENCE IN THE FIELD OF T...
- Biospace med, Total Solution to Orthopedic Imaging
- bioMerieux , Diagnosis and Prognosis of Heart Failure
- Transgene, therapeutic vaccine candidate TG4040 d...
-
▼
October
(8)
Friday, October 19, 2007
bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First Indication for Sepsis Risk Assessment in the ICU
Oct. 18, 2007 - bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® B·R·A·H·M·S PCT®. The test will be used with critically ill patients on their first day of admission to the Intensive Care Unit (ICU) as an aid to assess their risk for progression to severe sepsis and septic shock... bioMérieux's Press Release -